HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see…
This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.
Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
‘WSJ News Exclusive | FDA Planning to Allow Clinical Trials of Pig Organ Transplants’ – WSJ
https://www.wsj.com/articles/fda-said-to-plan-pig-organ-transplant-clinical-trials-11656622411
AstraZeneca Shares Data At EASL And ESMO World GI For IMFINZI Combinations In Patients With Liver And Biliary Tract Cancers
survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve
TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Endo Posts Disappointing Data From Frozen Shoulder Trial
Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with…
NRx Pharmaceuticals Announces FDA Declines Emergency Use Authorization For ZYESAMI For Subgroup Of Patients With Critical COVID-19 At Immediate Risk Of Death From Respiratory Failure Despite Treatment With Approved Therapy, Including Remdesivir
Focus is now on NRX-101 for Bipolar Depression with Suicidality
RADNOR, Pa., July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals"), a clinical-stage
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca’s COVID-19 Vaccine
Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents…